Platelet-Rich Plasma in the Treatment of Patients With Idiopathic Carpal Tunnel Syndrome
Carpal Tunnel Syndrome
About this trial
This is an interventional treatment trial for Carpal Tunnel Syndrome focused on measuring Carpal Tunnel Syndrome, Platelet-rich plasma
Eligibility Criteria
Inclusion Criteria:
- Patients with mild-to-moderate idiopathic CTS with clinical manifestations failed to respond to conservative treatment ( such as splint, medications, Physical therapy) for at least 3 months and they were diagnosed by electrophysiological study and musculoskeletal ultrasound.
Exclusion Criteria:
- Diabetes
- Hypothyroidism
- Rheumatoid arthritis
- Previous carpal tunnel decompressive surgery
- Cervical radiculopathy, polyneuropathy, brachial plexopathy, traumatic nerve injury, thoracic outlet syndrome
- Previous corticosteroid injection into the carpal tunnel in the preceding 4 weeks
- Anemia (hemoglobin <10gm%)
- Coagulopathy
- Pregnancy
Sites / Locations
- Mansoura University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
PRP Injection Group
Steroid injection Group
PRP Preparation: 16 ml of blood was obtained from each patient using special PRP kits (GD medical pharma, Dutch company). The blood was collected on citrated tubes with a mixing ratio of 9:1 by volume. Tubes underwent 1st centrifugation at speed of 3000 rpm (704g) for 3 minutes (to separate red blood cells from plasma). Plasma was then removed by syringe and then placed into another sterile tube with no anticoagulant and then underwent 2nd centrifugation at speed of at 4000 rpm (1252g) for 15 min. The supernatant platelet-poor plasma was then removed leaving 2 ml of PRP pellets in the sediment, and suspend the PRP pellets by gentle shaking of the tube. PRP is activated by adding 200 μl of 0.025 calcium chloride(Dhurat and Sukesh, 2014).
A single injection of methylprednisolone acetate 40 mg/ml using a technique similar to that described for the PRP injection